Nucleoside diphosphate kinase B, NDPK-B, NDPKB, NM23-H2, NM23B, EC 184.108.40.206, NDP kinase B, C-myc purine-binding transcription factor PUF, NDK B, NME2, puf, MGC111212.
NME2 takes an important part in the synthesis of nucleoside triphosphates other than ATP. NME2 negatively controls Rho activity by interacting with AKAP13/LBC. NME2 acts as a transcriptional activator of the MYC gene. NME2 binds DNA non-specifically. NME2 is a heterodimeric enzyme functioning as a nucleoside diphosphate kinase. NME1 and NME2 contain 152 amino acids, A and B polypeptide chains of the NM23 enzyme, respectively. NME2 is identical to the beta subunit of human erythrocyte NDP kinase. NDP kinases participate in the synthesis of nucleoside triphosphates, and NM23 is involved in the regulation of signal transduction by complexing with G proteins, causing activation/inactivation of developmental pathways.
Anti-human NME2 mAb, is derived from hybridization of mouse F0 myeloma cells with spleen cells from BALB/c mice immunized with recombinant human NME2 amino acids 1-152 purified from E. coli.
Mouse IgG2b heavy chain and κ light chain.
NME2 antibody was purified from mouse ascitic fluids by protein-A affinity chromatography.
1mg/ml containing PBS, pH-7.4, 10% Glycerol and 0.02% Sodium Azide.
Stability / Shelf Life
NME2 antibody has been tested by ELISA and Western blot analysis to assure specificity and reactivity. Since application varies, however, each investigation should be titrated by the reagent to obtain optimal results.